Special report: vaccines for the treatment of malignant melanoma.
This Special Report is a summary of the background for an evidence-based analysis of the phase I/II clinical trial data supporting currently open or recently closed phase III trials of melanoma vaccine therapy. It does not attempt to address the question as to whether the TEC criteria are met. Note, however, that since no melanoma vaccine as yet has FDA approval, the first criterion would not be met.
D000951:Antigens, Neoplasm / Q000276:immunology / Q000627:therapeutic use*; D054598:Blue Cross Blue Shield Insurance Plans; D019496:Cancer Vaccines / Q000276:immunology / Q000627:therapeutic use*; D002986:Clinical Trials as Topic; D006801:Humans; D007167:Immunotherapy / Q000379:methods; D008545:Melanoma / Q000628:therapy*; D009367:Neoplasm Staging; D012878:Skin Neoplasms / Q000628:therapy*; D013673:Technology Assessment, Biomedical; D014481:United States
D000951:Antigens, Neoplasm; D019496:Cancer Vaccines